All deployments

PharmaDeployment record

Caris Life Sciences

AI-based molecular signature

16.0median overall survival (months)

Built on
Whole Exome Sequencing, Whole Transcriptome Sequencing
Function
treatment selection
hazard ratio
0.48
survival with gem/nab-p
13.3 months
FDA approval date
November 2024
study publication
npj Precision Oncology

Source story

Caris AI Study Links Treatment Selection to Longer Survival in Pancreatic Cancer

Caris Life Sciences company profile →Pharma desk →

MachineCon USA · from AIM Media House

Where enterprise AI is decided

An invitation-led day for the CIOs, CDOs and Chief AI Officers who own enterprise AI strategy.

  • New York5th edition · 583 Park Avenue
  • Dallas1st edition

Register for MachineCon USASee MachineCon USA →

  • Keynote on the main stage, MachineCon New York 2025
  • AI150 award winners on stage, MachineCon New York 2025
  • At the tables, MachineCon New York 2025
  • Networking, MachineCon New York 2025